Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Pioglitazone on Serum FGF-23 Levels in Patients with Diabetic Kidney Disease
TCTR20210316009Phase 4Completed
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pioglitazone in diabetic glomerulosclerosis, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by None. Started Aug 2020; status: completed.
02
Drugs
pioglitazone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20210316009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210316009.